AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits
AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were hit Tuesday with a pair of putative antitrust class actions challenging a pay-for-delay deal that allegedly harmed consumers by keeping a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article